biosignature


Also found in: Dictionary, Wikipedia.

biosignature

(bī′ō-sĭg′nə-chər)
n.
1. A chemical or physical marker indicating the presence of life, especially something sought in geologic formations or in an extraterrestrial environment. Also called biomarker.
2. See biomarker.

biosignature

(bī″ō-sig′nă-chŭr) [ bio- + signature]
A particular group of proteins found in body fluid or tissue that identifies the tissue type or a molecular disease.
Mentioned in ?
References in periodicals archive ?
Newcastle's Biosignatures is developing a new system that uses advanced machine learning to analyse blood tests to diagnose illnesses at a much earlier stage.
Arney's analysis found that the oxygen-methane biosignature is likely to be stronger around a K star than a Sun-like star.
To implement precision psychiatry, we must be able to identify the biosignature of each patient's psychiatric brain disorder.
Although the Viking landers did test interesting samples suggestive of ancient life, their results were judged inconclusive --hardly surprising given that NASA conducted the mission nearly 20 years before the term "biosignature" had even been coined to describe evidence pointing to past or present life.
Cave biosignature suites: microbes, minerals, and Mars.
This study was supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019), China Medical University Hospital, Academia Sinica Taiwan Biobank, Stroke Biosignature Project (BM10501010037), NRPB Stroke Clinical Trial Consortium (MOST 105-2325-B-039-003), Ministry of Science and Technology, Taiwan (MOST103-2314-B-039-035MY3 and MOST105-2628-B-039-008-MY3), China Medical University Hospital, Taichung, Taiwan (DMR-105-066), and China Medical University, Taichung, Taiwan (CMU102ASIA-09), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, Katsuzo and Kiyo Aoshima Memorial Funds, Japan, and the Bureau of Health Promotion, Department of Health, Taiwan (DOH99HP-1205).
This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial Center (M0HW106-TDU-B-212-113004), China Medical University Hospital, Academia Sinica Taiwan Bioban kStroke Biosignature Project (BM10601010036), Taiwan Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan.
This study is supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW106TDU-B-212-113004); China Medical University Hospital; Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10601010036); Taiwan Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005); Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds, Japan.
Specifically, a single pathway that could best discriminate between disease and control was firstly extracted as the seed pathway (the first pathway biosignature), and the second pathway that could be added to the first pathway to obtain better classification performance was selected from those pathways that interacted with the first pathway in the PIN.
This study is supported by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), NRPB Stroke Clinical Trial Consortium (MOST 104-2325-B-039 -005), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan.